

## PUBLICATIONS AND PRESENTATIONS

### *Manuscripts and/or articles published as author or a contributor:*

#### 2004

The Effect of Montelukast on Rhinitis Symptoms in Patients with Asthma and Seasonal Allergic Rhinitis. *Current Medical Research and Opinions* 2004 20:1549-58. Authors: George Philip, **Anjali S. Nayak**, William E. Berger, Francisque Leynadier, France Vrijens, S.Balachandra Dass, Theodore F. Reiss.

Montelukast for Treating Fall Allergic Rhinitis: Effect of Pollen Exposure in Three Studies. *Annals of Allergy, Asthma and Immunology* 2004 Mar;92(3):367-73. Authors: Paul Chervinsky, MD; George Philip, MD; Marie-Pierre Malice, PhD; Jose Bardelas, MD; **Anjali Nayak, MD**; Jean-Louis Marchal, PhD; Janet van Adelsberg, MD; Jean Bousquet, MD; Carol A. Tozzi, PhD; Theodore F. Reiss, MD.

A Review of Montelukast in the Treatment of Asthma and Allergic Rhinitis. *Expert Opinion on Pharmacotherapy* 2004 5(3):679-686. Author: **Anjali Nayak, M.D.**

#### 2003

A Randomized Trial of Etanercept as monotherapy for psoriasis. *Arch Dermatol* 2003 Dec;139(12):1627-32. Authors: Alice B. Gottlieb, Clinical Research Center, New Brunswick, NJ; Robert T. Matheson, Oregon Medical Research Center; Nicholas Lowe, Clinical Research Specialists; Gerald G. Krueger, University of Utah Department of Dermatology; Sewon Kang, University of Michigan Department of Dermatology; Bernard S. Goffe, Minor James Medical; Anthony A. Gaspari, University of Rochester Medical Center; Mark Ling, MedaPhase, Inc.; Gerald D. Weinstein, University of California, Irvine, CA; **Anjali Nayak, Innovative Clinical Solutions, Inc.**; Kenneth B. Gordon, Northwestern University Medical Center, Anyang Feng, Immunex Corp.; M.E. Lebsack, Immunex Corp.

The Asthma and Allergic Rhinitis Link. *Allergy and Asthma Proceedings* 2003 Nov-Dec;24(6):395-402. Author: **Anjali S. Nayak, M.D.**

Tolerability of Re-Treatment with Omalizumab, a Recombinant Humanized Monoclonal Anti-IgE Antibody, During a Second Ragweed Pollen Season in Patients with Seasonal Allergic Rhinitis. *Allergy and Asthma Proceedings* 2003 Sep-Oct;24(5):323-29. Authors: **Anjali Nayak, MD**, Thomas Casale, MD, S David Miller, MD, John Condemi, MD, Margaret McAlary, MS, Angel Fowler-Taylor, RPh, Giovanni Della Cioppa, MD, Niroo Gupta, MD, PhD.

The Health-Related Quality of Life Effects of Once-Daily Cetirizine HCl in Patients with Seasonal Allergic Rhinitis: A Randomized Double-Blind Placebo-Controlled Trial. *Clinical & Experimental Allergy* 2003; 33:351-358. Authors: Michael J. Noonan, Allergy Associates, P.C. Portland, OR; Gordon D. Raphael, MD, George Washington University, Bethesda, MD; **Anjali Nayak, MD, Asthma & Allergy Research Associates, SC, Normal, IL**; Leon Greos, MD, Clinical Research Centers of Colorado, Wheat Ridge, CO; Abayomi Olufade, PharmD, MS, Pfizer, Inc. New York, NY; Nancy Kline Leidy, PhD, MEDTAP International Inc., Bethesda, MD, Douglass Champan, MS, Pfizer Inc, New York, NY; Benjamin Kramer, MD, Pfizer Inc., New York, NY.

2002

Efficacy and Safety of Beclomethasone Dipropionate Extrafine Aerosol in Childhood Asthma\* A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study. *Chest* 2002 Dec;122(6):1956-65.

Authors: **Anjali Nayak, MD**, Robert Lanier, Steven Weinstein, Patti Stampone, Michael Welch

A Common Pathway: Asthma and Allergic Rhinitis. *Allergy and Asthma Proceedings* 2002 Nov-Dec;23(6):359-65. Authors: **Anjali Seth Nayak, MD**, **University of Illinois College of Medicine, Peoria, IL**.

Omalizumab Improves Asthma-related Quality of Life in Children with Allergic Asthma. *Pediatrics* 2002 Nov;110(5). Authors: Robert F. Lemanske, Jr. MD, University of Wisconsin, Madison, WI; **Anjali Nayak, MD**, **University of Illinois, Peoria, IL**; Margaret McAlary, MS, Novartis Pharmaceuticals Corp, East Hanover, NJ; Francois Everhard, PhD, Novartis Pharma AG, Basel, Switzerland; Angel Fowler-Taylor, RPh, Novartis Pharmaceuticals Corp, East Hanover, NJ; Niroo Gupta, MD, Novartis Pharmaceuticals Corp, East Hanover, NJ.

Update on Pediatric Asthma: Current Issues and Management Strategies. A supplement to *Pediatric News - Proceedings of a Clinical Roundtable*. James P. Kemp, MD; Jay A. Markson, MD; **Anjali S. Nayak, MD**; Gary Rachelefsky, MD; Stanley J. Szeffler, MD.

Effective dose range of Mometasone furoate nasal spray in the treatment of acute rhinosinusitis. *Annals of Allergy, Asthma and Immunology* Vol. 89, September 2002. **Anjali S. Nayak, MD**, **University of Illinois, College of Medicine, Peoria, IL**; Guy A. Settipane, MD, Asthma, Nasal Disease & Allergy Research of New England, Providence, RI; Andrew Pedinoff, MD, Princeton Allergy & Asthma Research, Princeton, NJ; B. Lauren Charous, MD, Milwaukee Medical Clinic, Advanced Healthcare, SC, Milwaukee, WI; Eli O. Meltzer, MD, Allergy & Asthma Medical Group & Research Center, APC, San Diego, CA; William W. Busse, MD, University of Wisconsin Clinical Sciences Center, Madison, WI; S. James Zinreich, MD; Johns Hopkins Medical Institutions, Baltimore, MD; Richard R. Lorber, MD, Schering-Plough Research Institute, Kenilworth, NJ; Ger Rikken, MD, Schering-Plough Research Institute, Kenilworth; Melvyn R. Danzig, PhD, Schering-Plough Research Institute, Kenilworth; and the Nasonex Sinusitis Group.

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. *Annals of Allergy, Asthma and Immunology* Vol. 88, June 2002. Authors: **Anjali S. Nayak, MD**, **University of Illinois, College of Medicine, Peoria, IL**; George Philip, MD., Merck & Co., Rahway, NJ; Susan Lu, PharmD, Merck & Co., Rahway, NJ; Marie-Pierre Malice, PhD, Merck & Co., Rahway, NJ; Theodore F. Reiss, MD, Merck & Co., Rahway, NJ; and Montelukast Fall Rhinitis Investigator Group.

2001

Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis. *JAMA* Vol. 286 no. 23, December 19, 2001. Authors: Thomas B. Casale, MD, Department of Medicine, Creighton University, Omaha, NE; John Condemi, MD, University of Rochester, Rochester, NY; Craig LaForce, MD, North Carolina Clinical Research Institute, Raleigh, NC; **Anjali Nayak, MD**, University of Illinois at Chicago, Chicago, IL; Michael Rowe, MD, Michigan Respiratory Health and Research Institute, Novi, MI; Marc Watrous, PhD, Genentech, Inc., San Francisco, CA; Margaret McAlary, MS, Novartis Pharmaceuticals Corp., East Hanover, NJ; Angel Fowler-Taylor, RPh, Novartis Pharmaceuticals Corp., East Hanover, NJ; Amy Racine, PhD, Novartis Pharma AG, Basle, Switzerland; Niroo Gupta, MD, PhD, Novartis

Pharmaceuticals Corp., East Hanover, NJ; Robert Frick, MD, Genentech, Inc., San Francisco, CA; Giovanni Della Cioppa, MD, Novartis Horsham Research Centre, Horsham, England.

**Nayak AS**, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. *Allergy*, 56 (11): 1077-1080, November 2001. Efficacy and tolerability of once-daily 5mg desloratadine, an H-1-receptor antagonist, in patients with seasonal allergic rhinitis – Assessment during the spring and fall allergy seasons. *Clinical Drug Investigation*, 21 (1): 25-32, 2001.

Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab). *Pediatrics Vol. 108 No. 2, August 2001*. Authors: Henry Milgrom, MD, National Jewish Medical and Research Center, Denver, CO; William Berger, MD, Southern California Research Center, Mission Viejo, CA; **Anjali Nayak, University of Illinois, Peoria, IL**, Niroo Gupta, MD, Novartis Pharmaceuticals, East Hanover, NJ; Stephen Pollard, MD, Allergy & Asthma Research Institute, Louisville, KY; Margaret McAlary, Novartis Pharmaceuticals, East Hanover, NJ; Angel Fowler, RPh, Novartis Pharmaceuticals, East Hanover, NJ; Patricia Rohane, MD, Schering-Plough Corporation, Kenilworth, NJ.

Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. *International Journal of Dermatology* 2001, 40, 1-5. Johannes Ring, MD; Rudiger Hein, MD; Anke Gauger, MD; Edwin Bronsky, MD; Bruce Miller, MD; and the Desloratadine Study Group. (Cited as trial site)

Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. *Allergy* 2001;56(11):1077 -80. Authors: **A.S. Nayak, MD, School of Medicine, University of Illinois, Peoria, IL**; E. Schenkel, MD, Valley Clinical Research Center, Easton, PA.

Mometasone Furoate: Efficacy and Safety in Moderate Asthma Compared with Beclomethasone Dipropionate. *Annals of Allergy, Asthma & Immunology* 86 (2):203-10, February 2001. Authors: Robert A. Nathan, MD, Asthma and Allergy Associates, PC, Colorado Springs, CO; **Anjali S. Nayak, MD, Asthma and Allergy Research Associates, PC, Normal, IL**; David F. Graft, MD, Park Nicollet Clinic, Minneapolis, MN; Michael Lawrence, MD, Center for Clinical Research, Taunton, MA; Frank J. Picone, MD, Allergy and Asthma Consultants, PC, Tinton Falls, NJ; Tahir Ahmed, MD, Mount Sinai Medical Center, Miami Beach, FL; James Wolfe, MD, Allergy and Asthma Associates, San Jose, CA; Mark L. Vanderwalker, MD, Clinical Research of the Ozarks, Rolla, MO; Keith B. Nolop, MD, Schering-Plough Research Institute, Kenilworth, NJ; Judy E. Harrison, MD, Schering-Plough Research Institute, Kenilworth, NJ.

Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis, Assessment during the Spring and Fall Allergy Seasons. *Clin Drug Invest* 21 (1):25-32, 2001. Authors: Eli O. Meltzer, Allergy and Asthma Medical Group and Research Center, San Diego, California, USA; Bruce M. Prenner, Allergy Associates Medical Group, San Diego, California, USA; **Anjali Nayak, Peoria School of Medicine, University of Illinois, Peoria, Illinois, USA**; and the Desloratadine Study Group.

## 2000

Salmeterol and Fluticasone Propionate Combined in a New Dry Powder Inhalation Device for the Treatment of Asthma: a randomized, double-blind, placebo-controlled trial. *Journal of Allergy and Clinical Immunology* 105 (6 PT 1):1108-1116, June 2000. Authors: M. Kavuru, J. Melamed, G. Gross, C. Laforce, K. House, B. Prillman, L. Batinger, A. Woodring, T. Shah.

Once Daily Mometasone Furoate Dry Powder Inhaler in the Treatment of Patients with Persistent Asthma. *Annals of Allergy, Asthma, & Immunology* 84(4):417, April 2000. **Anjuli S Nayak, MD, Asthma & Allergy Research Associates, SC, Normal, IL and Dept. of Pediatrics, Peoria School of Medicine, Peoria, IL;** Charles Banov, MD, Allergy & Asthma Ctrs of Charleston, PA, Charleston, SC; Jonathan Corren, MD, Allergy Research Foundation, Inc., Los Angeles, CA; Barry K Feinstein, MD, Virginia Allergy & Pulmonary Associates, PC, Richmond, VA; Anthony Floreani, MD, University of Nebraska Medical Center, Omaha, NE; Bruce F Friedman, MD, Allergy, Asthma, Bronchitis and Immunology Associates, Foundtain-Valley, CA; Alan Goldsobel, MD, Allergy & Asthma Associates, San Jose, CA; Gregory M Gottschlich, MD, Allergy & Asthma Affiliates Research Center, Cincinnati, OH; Paul J Hannaway, MD, Allergy Affiliates Inc., Salem MA; Kathy L Lampl, MD, Asthma & Allergy Associates, Rockville, MD; Robert J Lapidus, MD, Rocky Mountain Pulm. Medical Clinical Research, Wheat Ridge, CO; Michael Lawrence, MD, Center for Clinical Research, Taunton, MA; William Lumry, MD, Allergy & Asthma Research Associates, Dallas, TX; Zev Munk, MD, Breco Research, Houston, TX; David Pearlman, MD, Rockland Pulmonary Associates, PC, Denver, CO; Anthony T Scardella, MD, Asthma & Allergy Center at St. Peter's Medical Center, New Brunswick, NJ; Eric J Schenkel, MD, Valley Clinical Research Center, Easton, PA; Allen T Segal, MD, Allergy Associates Research, Dallas, TX; Nathan Segall, MD, Georgia Allergy & Respiratory Institute, Atlanta, GA; Bernard Silverman, MD, Long Island College Hospital, Brooklyn, NY; Lucy Shneyer, MS, Schering-Plough Research Institute, Kenilworth, NJ; Keith B Nolop, MD, Schering-Plough Research Institute, Kenilworth, NJ; and Judy E Harrison, MD, Schering-Plough Research Institute, Kenilworth, NJ

Combined Salmeterol 50mcg and Fluticasone Propionate 250mcg in the Diskus Device for the Treatment of Asthma. *American Journal of Respiratory and Critical Care Medicine*, 161 (2 PT 1) :527-34, February 2000. Authors: G. Shapiro, W. Lumry, J. Given, M.V. White, A. Woodring, L. Batinger, K. House, B. Prillaman, T. Shah. (Cited as trial site)

### 1999

A Six-Month, Placebo-Controlled Comparison of the Safety and Efficacy of Salmeterol or Beclomethasone for Persistent Asthma. *Annals of Allergy, Asthma and Immunology*, 82 (6) :521-9, June 1999. Authors: R.A. Nathan, J.L. Pinnas, H.J. Schwartz, J. Grossman, S.W. Yancy, A.H. Emmett, K.A. Rickard.

The Emerging Role of Leukotriene Antagonists in Asthma Therapy. *Chest* 115(2):313-316, February 1999. Authors: B.J. Lipworth.

A Multiple-dosing, Placebo-controlled Study of Budesonide Inhalation Suspension Given Once or Twice Daily for Treatment of Persistent Asthma in Young Children and Infants. *Pediatrics*, 103(2): 414-21, February 1999. Authors: J.W. Baker, M. Mellon, J. Wald, M. Welch, M. Cruz-Rivera, K. Walton-Bowen.

Inhaled Corticosteroids Versus Anti-Leukotrienes: A Literature Review on the Clinical Effects. *Allergy, Supplement* 50:43-6, 1999. Authors: P.W. Ind.

Leukotriene-Receptor Antagonists. *Lancet*, 353(9146):57-62, January 2, 1999. Authors: B.J. Lipworth.

1998

Zafirlukast Improves Asthma Symptoms and Quality of Life in Patients with Moderate Reversible Airflow Obstruction. *The Journal of Allergy and Clinical Immunology* 102(6 PT 1) : 935-942, December 1998. Authors: R.A. Nathan, J.A. Bernstein, L. Bielory, C.M. Bonuccelli, W.J. Calhoun, S.P. Galant, L.A. Hanby, J.P. Kemp, J.W. Kylstra, **A.S. Nayak**, J.P. O'Connor, H.J. Schwartz, D.L. Southern, S.L. Spector, P.V. Williams.

The Inflammatory Nature of Allergic Disease. *Clin. Exp. Allergy* 28 Supplement 6:20-24, December 1998. Authors: S.R. Durham.

Alternative Agents for Anti-Inflammatory Treatment of Asthma. *The Journal of Allergy and Clinical Immunology*, 102(4 Pt 2):S23-35, October 1998. Authors: S.J. Szeffler, H.S. Nelson.

The Effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *The Journal of Allergy and Clinical Immunology* 101(2 Pt 1): 157-162, February 1998. Authors: **Anjuli S Nayak, MD, Asthma, Allergy, and Immunology (private practice), Normal, IL**; Mark H Ellis, MD, Department of Allergy/Immunology, Orange, CA; Gary N. Gross, MD, University of Texas Southwestern School of Medicine, Dallas, TX; Louis M Mendelson, MD, Department of Allergy/Immunology, University of Connecticut School of Medicine, West Hartford, CT; Eric J Schenkel, MD, Department of Allergy/Immunology, Hahnemann University, Easton, PA; Bobby Q. Lanier, MD, Harrison Department of Allergy/Immunology, Harris Hospital, Fort Worth, TX; Brandon Simpson, BS, Rhone-Poulenc Rorer, Colleagueville; Mary Ellen Mullin, MT, Rhone-Poulenc Rorer, Colleagueville; and Joseph A. Smith, MD, Astra USA, INC., Westborough

**Abstract accepted for publication:**

Novel Amb a 1 CpG Oligodeoxyribonucleotide Conjugate Ragweed Vaccine Administered to Children. *Accepted for publication at the 62<sup>nd</sup> Annual American Academy of Allergy, Asthma & Immunology*, Miami Beach, Florida, March 3-7, 2006. Authors: **A.S. Nayak**, I. Tripathy, D. Levitt.

Ciclesonide has no Effect on Growth in Prepubertal Children with Mild, Persistent Asthma, Irrespective of Age and Gender. *Accepted for publication at the 62<sup>nd</sup> Annual American Academy of Allergy, Asthma & Immunology*, Miami Beach, Florida, March 3-7, 2006. Authors: **A. Nayak**, O. Herrera, S. Kundu, M. Lloyd, D. Banerji.

**Abstract submitted for publication:**

Ciclesonide Has No Effect on Growth Velocity, Skeletal Maturity, and Hypothalamic-Pituitary-Adrenal-Axis Function in Prepubertal Children with Mild, Persistent Asthma. *Submitted for publication at The American Academy of Otolaryngic Allergy*, Toronto, Canada, September 17-20, 2006. Authors: D Skoner, M Noonan, **A Nayak**.

**Manuscripts accepted for publication:**

Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison. *Accepted for publication in Journal of the American Academy of Dermatology*. Authors: Zoe Draelos, MD, **Anjuli Nayak, MD**, David Pariser, MD, Jerome L Shupack, MD, Katie Chon, RPh, Beatrice Abrams, PhD, Carle F Paul, MD.

Mometasone Furoate Improves Congestion in Patients with Moderate-to-Severe Seasonal Allergic Rhinitis. *Accepted for publication in **Annals of Pharmacotherapy***. Authors: William E. Berger, MD, **Anjali S. Nayak, MD**.

Effectiveness of Azelastine Nasal Spray Compared with Oral Cetirizine in Patients with Seasonal Allergic Rhinitis. *Accepted for Publication in **Clinical Therapeutics***. Authors: Jonathon Corren, MD; William Storms, MD; Jonathan Berstein, MD; William Berger, MD; **Anjali Nayak, MD**; and Harry Sacks, MD; for the Azelastine Cetirizine Trial No. 1 (ACT 1) Study Group.

Efficacy and Safety of Desloratadine/Pseudoephedrine 2.5/120 mg BID Tablet Versus the Components in the Treatment of Patients with Seasonal Allergic Rhinitis. *Accepted for publication in **Allergy and Asthma Proceedings***. Authors: Paul Chervinsky, **Anjali Nayak**, Anthony Rooklin.

**Manuscripts submitted for publication:**

The Judicious Use of Antibiotics and Intranasal Corticosteroids in Acute Rhinosinusitis. *Submitted for publication in **American Family Physician***. Authors: **Anjali S. Nayak, M.D.**

Acute Rhinosinusitis: New Management Approaches for Primary Care. *Submitted for publication in **Journal of Infectious Diseases***. Authors: **Anjali S. Nayak, M.D.**

Ciclesonide Improves Lung Function and is Well Tolerated in Patients with Severe, Persistent Asthma. *Submitted for publication in **American Journal of Respiratory and Critical Care Medicine***. Authors: William Busse, Michael Kaliner, David Bernstein, **Anjali Nayak**, Sudeep Kundu, Donald Banerji.

Inhaled Mometasone Furoate from an HFA-227 Metered Dose Inhaler Reduces Oral Prednisone Requirements and Improves Lung Function of Patients with Severe Persistent Asthma. *Submitted for publication in **Respiratory Medicine***. Authors: Jill P. Karpel, MD, **Anjali Nayak, MD**, William Lumry, MD, Timothy Craig, DO, Edward Kerwin, MD, James E. Fish, MD, Barry Lutsky, MD.

Immunopathology of Psoriasis. *Submitted for publication in **Clinical Immunology***. Author: **Anjali Nayak, MD**.

Psoriasis Treatment Modalities. *Submitted for publication in **Clinical Immunology***. Author: **Dr. Anjali Seth Nayak, University of Illinois College of Medicine**.

Safety and Efficacy of Intermittent Treatment with Etanercept in Patients with Psoriasis. *Submitted for publication in **Journal of the American Academy of Dermatology***. Authors: **Anjali S. Nayak, MD**; Kenneth B. Gordon, MD; Alice B. Gottlieb, MD, PhD; Craig L. Leonardi, MD; Boni E. Elewskim, MD; Andrea Wang, MA; Angelika Jahreis, MD, PhD; and Ralph Zitnik, MD.

**National and International Abstracts Submitted as author or contributor:**

**National and International Abstracts Presented and Published as Author or Contributor:**

2005

Phase I Study of AMB A 1 Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Children. Presented at *The American College of Allergy, Asthma & Immunology, Anaheim, California, November 4-9, 2005*. Authors: **A S Nayak**, I Tripathy and D Levitt.

Mometasone Furoate Nasal Spray Once Daily is Effective in Severe Nasal Congestion Associated with Seasonal Allergic Rhinitis. Presented at *The American College of Allergy, Asthma & Immunology, Anaheim, California, November 4-9, 2005*. Authors: WE Berger, **AS Nayak**, H Staudinger, D Gates.

Monotherapy With Inhaled Corticosteroids: Still the Cornerstone of Asthma Therapy. *Presented at III European Asthma Congress, Athens, Greece, October 20-23, 2005*. Author: **Anjali S. Nayak**.

A New Generation of Inhaled Corticosteroid Therapy. *Presented at III European Asthma Congress, Athens, Greece, October 20-23, 2005*. Author: **Anjali S. Nayak**.

R411 Treatment Reduces Exacerbation and Attenuates FEV<sub>1</sub> Fall Following Steroid Withdrawal in Moderate Asthma. *Presented at the 2005 European Respiratory Society, Copenhagen, Denmark, September 17-21, 2005*. Authors: Alexis D Rames, MD; William B Busse, MD; Louis Renzetti, PhD and **Anjali S. Nayak, MD**.

Safety Profile of Fexofenadine in Children Aged 6 Months to 2 Years with Allergic Rhinitis. *Presented at World Allergy Congress, Munich, Germany June 26-July1, 2005*. Authors: **Nayak, Anjali, Peoria School of Medicine, University of Illinois, Normal**; Hampel, Frank C, Central Texas Health Research, New Braunfels; van Bavel, Julius H, Allergy and Asthma Associates, Austin; Kittner, Barbara, Aventis, Bridgewater.

The Novel Inhaled Corticosteroid, Ciclesonide, is Effective and Well Tolerated in Adults and Adolescents with Severe Asthma. *Presented at the 61<sup>st</sup> Annual American Academy of Allergy, Asthma & Immunology Meeting, San Antonio, Texas, March 18-22, 2005*. Authors: W Busse, M Kaliner, D Bernstein, **A Nayak**, S Kundu, S Williams, J Fish, D Banerji.

Efficacy and Safety of Etanercept in an Integrated Multistudy Database of Patients with Psoriasis. *Presented at the 61<sup>st</sup> Annual American Academy of Allergy, Asthma & Immunology Meeting, San Antonio, Texas, March 18-22, 2005*. Authors: **A Nayak** and R Zitnik.

Tolerability and Treatment Response at Starting Doses of Triamcinolone Acetonide AQ and Budesonide AQ in Patients with Seasonal Allergic Rhinitis. *Presented at Western Society of Allergy, Asthma and Immunology (WSAAI), Princeville, Hawaii, January 23-27, 2005*. Authors: **A Nayak**, W Berger, Y Liao, J Garcia, G Georges and the Study 4007 Investigator Group; Normal, IL, Mission Viejo, CA, Bridgewater, NJ.

2004

Daclizumab Reduces Eosinophils and Prolongs Time to Exacerbation in Patients with Moderate to Severe Chronic Persistent Asthma. *Presented at The American College of Allergy, Asthma & Immunology, Boston, MA, November 12-17, 2004.* Authors: E. Israel, W. Busse, J. Baker, B. Charous, **A. Nayak**, D. Pearlman, H. Nelson, J. Corren, V. Vexler, D. Young, R. Shames.

Ciclesonide does not Suppress the Hypothalamic-Pituitary-Adrenal-Axis Function in Patients with Severe Persistent Asthma: Results of a Long-Term Study. *Presented at The American College of Allergy, Asthma & Immunology, Boston, MA, November 12-17, 2004.* Authors: **Nayak A**, Nathan R, Williams J, Kundu S, Lloyd M, Banerji D.

Effect of Desloratadine on Quality of Life and Functional Sleep Outcome in Patients with Symptomatic Seasonal Allergic Rhinitis. *Published at EAACI, Amsterdam, 2004.* Authors: L E Mansfield, **A S Nayak**, T E Weaver, N J Amar, M F Goldstein, P Chervinsky, A G Harris.

Combination of Montelukast and Loratadine Provides Added Benefit for Relief of Symptoms of Seasonal Allergic Rhinitis (SAR). *Presented at the 2004 European Respiratory Society, Glasgow, Scotland, September 4-9, 2004.* Authors: G Philip, EO Meltzer, **AS Nayak**, MP Malice.

Efficacy of Etanercept in an Integrated Multi-Study Database of Patients with Psoriasis. *Presented at the 12<sup>th</sup> International Congress of Immunology and the 4<sup>th</sup> Annual Meeting, July 18-23, 2004, Montreal, Canada.*

Efficacy and Safety of Efalizumab in Patients with Moderate to Severe Plaque Psoriasis: Pooled Results from Three Phase III Randomized, Placebo-Controlled Trials. *Presented at the American Academy of Allergy, Asthma, and Immunology 2004 Annual Meeting, March 19-23, 2004, San Francisco, CA.* Author: **A Nayak, University of Illinois, Peoria, IL.**

2003

Asthma: From Genes to Clinical Management – Clinical Symposium on Therapeutic Options in Asthma. *Presented at the XVII World Asthma Congress, July 5-8, 2003, Saint-Petersburg, Russia.*

The Efficacy and Safety of a T-Cell Modulator, Efalizumab (Raptiva [trade]), in Patients with Moderate to Severe Plaque Psoriasis: Results from Phase III Trials. *Presented at the Federation of Clinical Immunology Society Third Annual Meeting, May 15-19<sup>th</sup> 2003, Paris, France.*

ENBREL® (Etanercept) Monotherapy in Patients with Psoriasis: Clinical and Pathologic Improvements. *Presented at the American Academy of Allergy Asthma & Immunology 60<sup>th</sup> Annual Meeting, March 7-12, 2003, Denver, CO.* Authors: **A. Nayak (Peoria, IL)**, R. Zitnik (Seattle, WA)

2002

Improvements in Pulmonary Function with Mometasone Furoate Dry Powder Inhaler in Patients with Persistent Asthma Previously Maintained on Inhaled Short-Acting B<sub>2</sub>-Adrenergic Agonists: Efficacy Analysis Based on Baseline FEV<sub>1</sub>. *Presented at the American College of Allergy, Asthma & Immunology Annual Meeting, November 16 & 17<sup>th</sup> 2002, San Antonio, Texas.* Authors: **A.S. Nayak, MD, Asthma and Allergy Research Associates, SC, Normal, IL, USA**; J.P. Kemp, MD, Allergy and Asthma Medical Group and Research Center, San Diego, CA, USA; J.J. Murray, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA; L. Schneyer, Schering-Plough Research Institute, Kenilworth, NJ, USA.

Efficacy of Beclomethasone Dipropionate (BDP) Extrafine Aerosol Following Switch From Conventional BDP in Children with Asthma. *Presented at the American Academy of Asthma, Allergy, and Immunology 58<sup>th</sup> Annual meeting, March 1-March 6, 2002, New York, NY.* Authors: **A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL**, Stanley J. Szeffler, National Jewish Medical Research Center, Denver, CO, Soren Pedersen, University of Odense & Kolding Hospital, Kolding Denmark.

Systemic Safety of New Beclomethasone Dipropionate Extrafine Aerosol in Childhood Asthma. *Presented at the American Academy of Asthma, Allergy, and Immunology 58<sup>th</sup> Annual meeting, March 1-March 6, 2002, New York, NY.* Authors: M.J. Welch, Allergy & Asthma Medical Group & Research Center, San Diego, CA; S. F. Weinstein, Allergy & Asthma Specialist Medical Group, Huntington Beach, CA; R. Lanier, Lanier Education and Research Network, Fort Worth, TX; **A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL**; P. Stampone, 3M Pharmaceuticals, St. Paul, MN.

New Beclomethasone Dipropionate Extrafine Aerosol Is Effective Pediatric Asthma Therapy. *Presented at the American Academy of Asthma, Allergy, and Immunology 58<sup>th</sup> Annual meeting, March 1-March 6, 2002, New York, NY.* Authors: S. F. Weinstein, Allergy & Asthma Specialist Medical Group, Huntington Beach, CA; M.J. Welch, Allergy & Asthma Medical Group & Research Center, San Diego, CA; Lanier Education and Research Network, Fort Worth, TX; **A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL**; P. Stampone, 3M Pharmaceuticals, St. Paul, MN.

Long-Term Safety of Extrafine and Conventional Beclomethasone Dipropionate Aerosols in Pediatric Asthma. *Presented at the American Academy of Asthma, Allergy, and Immunology 58<sup>th</sup> Annual meeting, March 1-March 6, 2002, New York, NY.* Authors: Stanley J. Szeffler, National Jewish Medical Research Center, Denver, CO; **A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL**; Soren Pedersen, University of Odense & Kolding Hospital, Kolding Denmark.

Efficacy of Beclomethasone Dipropionate (BDP) Extrafine Aerosol Following Switch from Conventional BDP in Children with Asthma. *Presented at the American Academy of Asthma, Allergy, and Immunology 58<sup>th</sup> Annual meeting, March 1-March 6, 2002, New York, NY.* Authors: D. Donnell, 3M Pharmaceuticals, Loughborough, UK; **A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL**; Stanley J. Szeffler, National Jewish Medical Research Center, Denver, CO; Soren Pedersen, University of Odense & Kolding Hospital, Kolding Denmark.

Mometasone Furoate Reduces Oral Corticosteroid Requirements and Improves Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Severe Persistent Asthma. *Presented at the American Academy of Asthma, Allergy, and Immunology 58<sup>th</sup> Annual meeting, March 1-March 6, 2002, New York, NY.* Authors: J.P. Karpel, Montefior Medical Center, Bronx, NY; **A. Nayak, Peoria School of Medicine – University of Illinois, Normal, IL**; W. Lumry, Asthma and Allergy Research Associates, Dallas, TX; Timothy J. Craig, Penn State University College of Medicine, Hershey, PA; E. Kerwin, Clinical Research Institute of Oregon, LLC, Medford, OR; J.E. Fish, Department of Pulmonology Medicine, Thomas Jefferson University Hospital, Philadelphia, PA; U. Palm, Schering Plough, Kenilworth, NJ.

## 2001

New Beclomethasone Dipropionate Extrafine Aerosol is Effective in Children With Asthma. *Presented at the American College of Allergy, Asthma & Immunology (ACAAI), November 16<sup>th</sup>-18<sup>th</sup>, 2001.* Authors: **A. Nayak**, Normal, IL; R. Lanier, Fort Worth, TX; P. Stampone, St. Paul, MN.

Comparative long-term safety of extrafine and conventional formulations of beclomethasone dipropionate asthma. *Presented at the American College of Allergy, Asthma & Immunology (ACAAI), November 16<sup>th</sup>-18<sup>th</sup>, 2001.* Authors: S. Szeffler, Denver, CO; D. Staab, Berlin, Germany; **A. Nayak, Normal, IL**; U. Whan, Berlin, Germany; J. Warner, Southampton, UK; J. Vanden Burgt, St. Paul, MN.

Comparative pediatric efficacy of beclomethasone dipropionate (BDP) extrafine aerosol following switch from chlorofluorocarbon-BDP with long term follow-up. *Presented at the American College of Allergy, Asthma & Immunology (ACAAI), November 16<sup>th</sup>-18<sup>th</sup>, 2001.* Authors: S. Szeffler, Denver, CO; D. Staab, Berlin, Germany; **A. Nayak, Normal, IL**; U. Wahn, Berlin, Germany; J. Warner, Southampton, UK; J. Vanden Burgt, St. Paul, MN.

Xolair in the Treatment of Perennial Allergic Rhinitis. *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, New Orleans, March 2001.* Authors: P Chervinsky, New England Research Studies, North Dartmouth, MA; W Busse, University of Wisconsin Hospital, Madison, WI; T Casale, Creighton University Center, Omaha, NE; **A Nayak, Asthma and Allergy research Associates, Normal, IL**; I Tripathy, Clinical Research of the Ozarks, Inc, Rolla, MO; A Fowler-Taylor, Novartis Pharmaceuticals, East Hanover, NJ; N Gupta, Novartis Pharmaceuticals, East Hanover, NJ; P Rohane, Novartis Pharmaceuticals, East Hanover, NJ; H Shen, Novartis Pharmaceuticals, East Hanover, NJ.

Decongestant Effects of Desloratadine in Patients with Seasonal Allergic Rhinitis. *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, New Orleans, March 2001.*

Omalizumab (Xolair) Improves Rhinoconjunctivitis-Specific Quality of Life in Patients with Perennial Allergic Rhinitis. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: Busse W., Madison, WI; **Nayak A., Normal, IL**; Chervinsky P., North Dartmouth, MA, Casale T., Omaha, NE; Tripathy I., Rolla, MO; Bernstein J., Cincinnati, OH; Condemi J., Rochester, NY; Fowler Taylor A., East Hanover, NJ; Shen H., East Hanover, NJ; Hedgecock S., Horsham, UK; Fox H., Horsham, UK; Everhard F., Basel, Switzerland.

Omalizumab (Xolair) Improves Perennial Allergic Rhinitis in Patients Who Were Previously Unresponsive to Treatment with Nasal Steroids or Immunotherapy. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: Busse W., Madison, WI; **Nayak A., Normal, IL**; Chervinsky P., North Darmouth, MA, Casale T., Omaha, NE; Tripathy I., Rolla, MO; Bernstein J., Cincinnati, OH; Condemi J., Rochester, NY; Fowler Taylor A., East Hanover, NJ; Shen H., East Hanover, NJ; Hedgecock S., Horsham, UK; Fox H., Horsham, UK; Everhard F., Basel, Switzerland.

Long Term Use of Once-Daily Mometasone Furoate Is Effective and Well Tolerated in Patients with Mild to Moderate Persistent Asthma. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: **A.S. Nayak, MD, Asthma & Allergy Research Associates, SC, Normal, IL, USA**; K.L. Lampl, MD, Asthma & Allergy Associates, Rockville, MD, USA; N. Segall, MD, Georgia Allergy & Respiratory Institute, Atlanta, GA, USA; J. Harrison, MD, Schering-Plough Research Institute, Kenilworth, NJ, USA.

Asthma and Rhinitis Induced by Cockroach Allergen in an Urbanized Russian Community. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: **Anjuli S Nayak**, David Nayak, Sandra Knapp, Clinical Research Center, Normal, IL.

Treatment of Allergic Rhinitis with Montelukast Alone or in Combination with Loratadine in a Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: K Lis, K Malmstrom, **A Nayak**, G Philip, M-P Malice, TF Reiss, and the Montelukast Fall Rhinitis Investigator Group

Persistent Severe Cow's Milk Protein Allergy Secondary to Skin Contact. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: See-Long Wong and **Anjuli S. Nayak, Clinical Research Center, Normal, IL.**

Improvement in Rhinoconjunctivitis Quality of Life Outcomes in the Treatment of Fall Allergic Rhinitis by Montelukast Alone or in Combination with Loratadine in a Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. *Presented at the American Academy of Allergy, Asthma, and Immunology Meeting, New Orleans, March 2001.* Authors: G Philip, K Malmstrom, Merck & Co; **A Nayak, Clinical Studies Bloomington-Normal, Normal, IL**; Marie-Pierre Malice, Merck & Co; Theodore F Reiss, Merck & Co; and the Montelukast Fall Rhinitis Investigator Group, Merck & Co.

Omalizumab (Xolair) Improves Asthma-Specific Quality of Life (QOL) in Children with Allergic Asthma. *Presented at the World Asthma Meeting, Chicago, July 2001.* Authors: **Nayak A, ICSL, Normal, USA**; Milgrom H, National Jewish Medical and Research Center, Denver, USA; Berger W, Southern California Research Center, Mission Viego, USA; Pollard S, Asthma and Allergy Research Institute, Louisville, USA; Watrous M, Genentech, USA; Doyle J, Novartis, USA; McAlary M, Novartis, USA; Gupta N, Novartis, USA; Fowler Taylor A, Novartis, USA

No Gender Difference In Response To Treatment With Mometasone Furoate Among Patients With Mild to Moderate Persistent Asthma. *Presented at the American Thoracic Society Int. Conf., 2001.* Authors: J.P. Kemp, **A.S. Nayak**, D.I. Bernstein, G. Rachevsky, J.E. Harrison, K.B. Nolop.

Omalizumab (Xolair) is Effective and Well Tolerated in the Treatment of Children with Allergic Asthma. *Presented at the World Asthma Meeting, Chicago, July 2001.* Authors: Milgrom H, National Jewish Medical and Research Center, Denver, USA; **Nayak A, ICSL, Normal, USA**; Berger W, Southern California Research Center, Mission Viejo, USA; Pollard S, Asthma and Allergy Research Institute, Louisville, USA; Bensch G, Allergy, Immunology and Asthma Medical Group, Stockton, USA; Hampel F, Central Texas Health Research, New Braunfels, USA; McAlary M, Novartis, USA; Fick R, Genentech, USA; Fowler Taylor A, Novartis, USA; Gupta N, Novartis, USA

Effects of Age on Response to Treatment with Mometasone Furoate Among Patients with Mild to Moderate Persistent Asthma. *Presented at the ATS 2001 San Francisco, the 97<sup>th</sup> International Conference, San Francisco, May 2001.*

Desloratadine Relieves Nasal Congestion in Patients with Seasonal Allergic Rhinitis and Concurrent Asthma. *Presented at the American College of Allergy, Asthma, and Immunology, November 2000, Seattle. Annals of Allergy, Asthma and Clinical Immunology, 86(1):84, January 2001.* Authors: R. Natham, and the Desloratadine Study Group, Colorado Springs, CO.

## 2000

The Effects of Once-Daily Cetirizine HCL on Symptoms and Health-Related Quality of Life (HRQL) in Patients with Seasonal Allergic Rhinitis (SAR): Results of A Second Randomized Double-Blind Placebo Controlled Trial. *Presented at the American College of Allergy, Asthma, and Immunology, November 2000, Seattle. Annals of Allergy, Asthma and Clinical Immunology, 86(1):83, January 2001.* Authors: MJ Noonan, MD, Portland, OR; G Raphael, MD, Bethesda, MD; **AS Nayak, MD, Normal, IL**; L Greos, MD, Wheat Ridge, CO; AO Olufade, PharmD, MS; D Chapman, MS; B Kramer, MD, New York, NY.

Long-Term use of Corticosteroids in Children: Comparative Safety and Efficacy of an Extrafine Beclomethasone Dipropionate Aerosol and a Conventional PMDI. *Presented at the International Congress of Allergy, Asthma, and Immunology, October 2000, Australia.*

Rapid Onset of Action of Mometasone Furoate (MF) Administered Once Daily by Dry Powder Inhaler. *Presented at the European Respiratory Society Meeting, August 2000, Italy. (Also published in the European Respiratory Journal, August 2000).*

Desloratadine Relieves Nasal Congestion in Patients with Seasonal Allergic Rhinitis. *Presented at the Congress of the European Academy of Allergology and Clinical Immunology, July 2000, Spain.*

Desloratadine Relieves Nasal Congestion in Patients with Seasonal Allergic Rhinitis. *Presented at the XIXth Congress of the European Academy of Allergology and Clinical Immunology, July 2000, Lisbon, Portugal.*

Once-daily, Evening Dosing with Mometasone Furoate (MF) Improves Pulmonary Function in Patients with Mild to Moderate Asthma. *Presented at the American Thoracic Society Meeting, May 2000.*

RhuMAb-E25 (E25), Improves Quality of Life (QOL) In Children with Allergic Asthma. *Presented at the American Thoracic Society Meeting, May 2000. Published in American Journal of Respiratory and Critical Care Medicine, 161(3): Abstract issue, March 2000.*

The Efficacy and Safety of rhuMAB-E25 (E25) In Children with Allergic Asthma (AA). *Presented at the American Thoracic Society Meeting, May 2000. Published in Journal of Allergy and Clinical Immunology, 105(1), Pt.2, January 2000.* Authors: Milgram H, **Nayak AS**, Berger W.

The Efficacy and Safety of rhuMAB-E25 (E25) In Children with Allergic Asthma (AA). *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 2000.*

RhuMAB-E25 (E25), A Novel Therapy for the Treatment of Allergic Asthma (AA). *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 2000. Published in Journal of Allergy and Clinical Immunology, 105(1), Pt. 2, January 2000.* Authors: Busse W, Corren J, Lanier BQ, Lee T, **Nayak AS**.

Decongestant Effects of Desloratadine in Patients with Seasonal Allergic Rhinitis. *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 2000.*

Safety of Re-administration of rhuMAB-E25 in Seasonal Allergic Rhinitis (SAR). *Presented at the American College of Asthma, Allergy, and Immunology Meeting, November 1999, Chicago, IL. Annals of Allergy, Asthma and Immunology, 8(1):125, January 2000.* Authors: T. Casale, J. condemi, J.A. Bernstein, W. Busse, **A. Nayak**, R. Fick, A. Fowler-Taylor, N. Gupta, P.W. Rohane.

#### 1999

Once-daily Mometasone Furate dry powder is highly effective therapy for patients with mild to moderate persistent asthma. *Presented at the American College of Asthma, Allergy, and Immunology Meeting, November 1999, Chicago, IL.* Authors: **A.S. Nayak**, K.L. Lampl, N. Segall, K.B. Nolop,, and the C96-136 Study Group.

A Randomized Study Showing Lower Doses of Nebulized Albuterol Safe and Effective for Pediatric Asthmatics. *Presented at the American College of Asthma, Allergy, and Immunology Meeting, 1998, Philadelphia. Annals of Allergy, Asthma and Immunology, 82(1):77, January 1999.* Authors: J.P. Kemp, **A.S. Nayak**, M.J. Noonan, J. Oren, P.S. Covington, A. Kaplan.

HPA-Axis Function in Infants and Young Children with Persistent Asthma Treated for 52 Weeks with Budesonide Inhalation Suspension (BIS; Pulmicort Respules). *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 1999, Orlando, FL.*

Effects of Once-Daily Mometasone Furoate Dry Powder Inhaler (MF DPI) on FEV1 and AM PEFR in Patients with Mild to Moderate Persistent Asthma. *Presented at the European Respiratory Society Meeting, 1999, Spain.*

RhuMab-E25 Improves Quality of Life in Patients with Seasonal Allergic Rhinitis (SAR). *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 1999, Orlando, FL. Journal of Allergy & Clinical Immunology 103(1 Pt 2):S49, January 1999.* **Nayak A**, LaForec C, Rowe M, Watrou M, Fick R, McAlary M Gupta N, Fowler Taylor, Rohane PW.

HPA-Axis Function in Infants and Young Children with Persistent Asthma Treated for 52 Weeks with Budesonide Inhalation Suspension (BIS; Pulmicort Respules). *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, March 1999, Orlando, FL.*

Effects of Once-Daily Mometasone Furoate Dry Powder Inhaler (MF DPI) on FEV1 and AM PEFr in Patients with Mild to Moderate Persistent Asthma. *Presented at the European Respiratory Society Meeting, 1999, Spain.*

Randomized, Double-Blind, Parallel, Placebo-Controlled Multi-Center Trial Of Ipratropium Bromide Nasal Spray 0.06% in Patients with Seasonal Allergic Rhinitis. *Presented at the American College of Asthma, Allergy, & Immunology Meeting, November 1998, Philadelphia, PA. Annals of Allergy, Asthma, and Immunology, 82(1):109, January 1999.* Authors: W. Busse, R. Biondi, T. Casale, P. Chervinsky, R. Dockhorn, A. Finn, H. Kaiser, M. Kathan, C. Laforce, **A. Nayak**, et al.

### 1998

A Six-Month, Placebo-Controlled Comparison of the Safety and Efficacy of Salmeterol or Beclomethasone as Monotherapy for Persistent Asthma. *Presented at the American College of Asthma, Allergy, and Immunology Meeting, November 1998, Philadelphia, PA.*

Equivalence of Adding Zafirlukast versus Double-Dose Inhaled Corticosteroids in Asthmatic Patients Symptomatic on Low-Dose Inhaled Corticosteroids. *Presented at American Academy of Asthma, Allergy, and Immunology Meeting, March 1998, Washington DC.*

Addition of Zafirlukast Compared with Double Dosage of Inhaled Corticosteroids in Asthmatic Patients with Symptoms on Inhaled Corticosteroids. *Presented at the European Respiratory Society Meeting, 1998, Sweden.*

Asthma Severity as a Determinant for Selecting Appropriate Doses of Fluticasone Propionate (FP) or Beclomethasone Dipropionate (BDP). *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, 1998, Washington, DC.*

Alarming Asthma Prevalence Secondary to Cockroach and Mite Allergies in West Indian Island of Robinson Crusoe. *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, 1998, Washington DC.*

### 1997

Montelukast, a CysLT1 Receptor Antagonist, Decreases Peripheral Blood Eosinophils and Improves the Signs and Symptoms of Asthma Over a 3-Month Period. *Presented at the 1997 American Academy of Asthma, Allergy, and Immunology Annual Meeting and 1997 American Thoracic Society Annual Meeting, San Francisco, CA.* Authors: T.F. Reiss, P. Chervinsky, T. Edwards, R. Dockhorn, **A. Nayak**, J. Hess, J. Zhang, S. Shingo.

Zafirlukast Improves Nasal Congestion and Asthma Symptoms in Asthmatic Patients. *Presented at International Congress of Asthma, Allergy, and Clinical Immunology Meeting, 1997, Cancun, Mexico.*

Long Term Treatment of Asthma With Zafirlukast (ACCOLATE): Results of a 13-Week Multicenter Trial in Patients with Moderate Airflow Obstruction. *Presented at the International Congress of Asthma, Allergy, and Clinical Immunology Meeting, 1997, Cancun, Mexico.*

Fluticasone Propionate Administered Via The Diskus 500mcg Once Daily or 250mcg Twice Daily is Safe and Effective in Adult Patients With Asthma. *Presented at the American Thoracic Society Meeting, May 1997, San Francisco, CA.* Authors: D.P. Clifford, J. Adelglass, R. Zuwallack, **A. Nayak**, T. Bell, T. Edwards, J. Christenson, P. Wire, E. Field, S. Harding, A. Hamedani, K. Mussari.

Effect of 24-Week Salmeterol Therapy on Airway Hyperresponsiveness. *Presented at the American Thoracic Society Meeting, May 1997, San Francisco, CA.* Authors: J. Kemp, C. Kalberg, W. Anderson, A. Emmett, K. Rickard.

Salmeterol Improves Asthma-Specific Quality of Life in Patients with Moderate Persistent Asthma. *Presented at the AAAAI/AAI/CIS Meeting, February 1997, San Francisco, CA.*

Montelukast (MK-0476) A CysLT<sub>1</sub> Receptor Antagonist Improves Asthma Outcomes over a 3-Month Treatment Period. *Presented at the 1997 American Thoracic Society Annual Meeting, San Francisco, CA and European Respiratory Society Meeting, 1996, Stockholm.* Authors: T.F. Reiss, P. Chervinsky, T. Edwards, R. Dockhorn, **A. Nayak**, J. Hess, J. Zhang, S. Shingo.

Ocular Efficacy and Clinician Overall Evaluation of Intranasal Fluticasone Propionate (FP) Versus Loratadine (LOR) in Seasonal Allergic Rhinitis (SAR). *Presented at the American College of Asthma, Allergy, and Immunology Meeting, 1996, Boston, MA. Annals of Allergy, Asthma and Immunology, 78(1):128, January 1997.* Authors: J.H. van Bavel, P.H. Ratner, **A.S. Nayak**, D. Shulan, K.D. Reed, P.R. Rogenes, C.K. Cook.

#### 1996

Secondary Outcomes Analysis of Zileuton plus Usual Care versus Usual Care Alone in the Treatment of Patients with Asthma. *Presented at the American College of Asthma, Allergy, and Immunology Meeting, 1996, Boston, MA.* Authors: S.C. Lazarus, T.M. Lee, S. Wright, P. Sarocco, L. Rosenstein, S. Bialek-Smith, L. Dube, and the Zileuton Safety Trial Study Group.

Intranasal Fluticasone Propionate (FP) is More Effective Than Loratadine (LOR) For Treatment of Seasonal Allergic Rhinitis. *Presented at the American Academy of Asthma, Allergy, and Immunology Meeting, 1996, New Orleans, LA.*

Triamcinolone Acetonide Aqueous Nasal Spray Does Not Alter Adrenocortical Function in Children with Allergic Rhinitis. *Presented at the American Academy of Otolaryngology- Head and Neck Surgery Foundation Meeting, 1996, Washington DC and Western Society of Allergy & Immunology, 1996, Hawaii.*

#### Articles published with Dr. Nayak's citations

Coffey MJ, Wilfond B., Ross LF. Ethical Assessment of Clinical Asthma Trials Including Children Subjects. *Pediatrics 113 (1 Pt 1): 87-94, Jan. 2004.*

Scadding GK. Recent Advances in the Treatment of Rhinitis and Rhinosinusitis. *International Journal of Pediatric Otorhinolaryngology 67: S201-S204 Suppl. 1, Dec 2003.*

Benninger MS, Ahmad N., Marple BF. The Safety of Intranasal Steroids. *Otolaryngology-Head and Neck Surgery 129 (6): 739-750, Dec. 2003.*

- Borish L. Allergic Rhinitis: Systemic inflammation and implications for management. *Journal of Allergy and Clinical Immunology* 112 (6): 1021-1031, Dec. 2003.
- Stern RS. A Promising Step Forward in Psoriasis Therapy. *JAMA* 290 (23): 3133-3135, Dec 17, 2003.
- Kobayashi S., Endou M., Sakuraya F., et al. The Sympathomimetic actions of 1-ephedrine and d-pseudoephedrine: Direct Receptor Activation or Norepinephrine Release? *Anesth Analg* 97 (5): 1239-45, Nov. 2003.
- Holgate ST, Broide D. New Target for Allergic Rhinitis – A Disease of Civilization. *Nature Reviews Drug Discovery* 2 (11): 903-914, Nov. 2003.
- van Adelsberg J., Philip G., Pedinoff AJ., et al. Montelukast Improves Symptoms of Seasonal Allergic Rhinitis over a 4-Week Treatment Period. *Allergy* 58 (12): 1268-1276, Dec. 2003.
- Fox RW., Lockey RE. The Impact of Rhinosinusitis on Asthma. *Current Allergy and Asthma Reports* 3 (6): 513-518, Nov. 2003.
- Wilken JA., Kane RL., Ellis AK., et al. A Comparison of the Effect of Diphenhydramine and Desloratadine on Vigilance and Cognitive Function During Treatment of Ragweed-Induced Allergic Rhinitis. *Annals of Allergy Asthma & Immunology* 91 (4): 375-385, Oct. 2003.
- Marcus P. Dosing Inhaled Steroids in Asthma – Is Once-a-day Administration Effective? *CHEST* 124 (4): 1196-1198, Oct. 2003.
- Potter PC., Van Niekerk CH., Schoeman HS. Effects of Triamcinolone on Quality of Life in Patients with Persistent Allergic Rhinitis. *Annals of Allergy Asthma & Immunology* 91 (4): 368-374, Oct. 2003.
- Bukstein DA. Untitled. *Annals of Allergy Asthma & Immunology* 91 (4): 417-418, Oct. 2003.
- Stone KD. Atopic Diseases of Childhood. *Current Opinion in Pediatrics* 15 (5): 495-511, Oct. 2003.
- Salib RJ., Howarth PH. Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis. *Drug Safety* 26 (12): 863-893, 2003.
- Figueroa DJ., Borish L., Baramki D., et al. Expression of Cysteinyl Leukotriene Synthetic and Signalling Proteins in Inflammatory Cells in Active Seasonal Allergic Rhinitis. *Clinical and Experimental Allergy* 33 (10): 1380-1388, Oct. 2003.
- Murdoch D., Goa KL., Keam SJ. Desloratadine – An Update of its Efficacy in the Management of Allergic Disorders. *DRUGS* 63 (19): 2051-2077, 2003.
- Potter PC. Levocetirizine is Effective for Symptom Relief Including Nasal Congestion in Adolescents and Adult (PAR) Sensitized to House Dust Mites. *ALLERGY* 58 (9): 893-899, Sep. 2003.
- Corren J., Berkowitz R., Murray JJ., et al. Comparison of Once-Daily Mometasone Furoate Versus Once-Daily Budesonide in Patients with Moderate Persistent Asthma. *International Journal of Clinical Practice* 57 (7): 567-572, Sep. 2003

Schenkel E. Features of Mometasone Furoate Nasal Spray and its Utility in the Management of Allergic Rhinitis. *Expert Opinion of Pharmacotherapy* 4 (9): 1579-1591, Sep. 2003.

Didier A. Clinical Efficacy of Mometasone in Asthma. *Revue Francaise D Allergologie ET D Immunologie Clinique* 43 (5): 330-334, Sep. 2003.

Haberal I., Corey JP. The Role of Leukotrienes in Nasal Allergy. *Otolaryngol Head Neck Surg.* 129 (3): 274-9, Sep. 2003.

Richter A., Anton SF., Koch P., et al. The Impact of Reducing Dose Frequency on Health Outcomes. *Clinical Therapeutics* 25 (8): 2307-2335, Aug. 2003.

Storms WW. Minimal Persistent Inflammation, an Emerging Concept in the Nature and Treatment of Allergic Rhinitis: the Possible Role of Leukotrienes. *Annals of Allergy Asthma & Immunology* 91 (2): 131-140, Aug. 2003.

Wyrwich KW., Nelson HS., Tierney WM., et al. Clinically Important Differences in Health-Related Quality of Life for Patients with Asthma: An expert Consensus Panel Report. *Annals of Allergy Asthma & Immunology* 91 (2): 148-153, Aug. 2003.

Horak F., Stubner P., Zieglmeyer R., et al. Comparison of the Effects of Desloratadine 5-mg Daily and Placebo on Nasal Airflow and Seasonal Allergic Rhinitis Symptoms Induced by Grass Pollen Exposure. *ALLERGY* 58 (6): 481-485, June 2003.

Schmier J., Leidy NK., Gower R. Reduction in Oral Corticosteroids Use with Mometasone Furoate Dry Powder Inhaler Improves Health-Related Quality of Life in Patients with Severe Persistent Asthma. *Journal of Asthma* 40 (4): 383-393, 2003.

Parikh SA., Cho SH., Oh CK. Preformed Enzymes in Mast Cell Granules and Their Potential Role in Allergic Rhinitis. *Current Allergy and Asthma Reports* 3 (3): 266-272, May 2003.

Saengpanich S., deTineo M., Naclerio RM., et al. Fluticasone Nasal Spray and the Combination of Loratadine and Montelukast in Seasonal Allergic Rhinitis. *Arch Otolaryngol Head Neck Surg.* 129 (5): 557-62, May 2003.

Green RH., Brightling CE., Pavord ID., et al. Management of Asthma in Adults: Current Therapy and Future Directions. *Postgrad Med J* 79 (931): 259-67, May 2003.

Baena-Cagnani CE., Berger WE., DuBuske LM., et al. Comparative Effects of Desloratadine Versus Montelukast on Asthma Symptoms and Use of Beta(2)-Agonists in Patients with Seasonal Allergic Rhinitis and Asthma. *International Archives of Allergy and Immunology* 130 (4): 307-313, April 2003.

Gonyeau MJ., Partisano AM. A Clinical Review of Montelukast in the Treatment of Seasonal Allergic Rhinitis. *Formulary* 38 (6): 368-376, June 2003.

Baroody FM. Allergic Rhinitis: Broader Disease Effects and Implications for Management. *Otolaryngology-Head and Neck Surgery* 128 (5): 616-631, May 2003.

Nathan RA. Do Leukotriene Receptor Antagonists have a Place in Pharmacotherapy of Allergic Rhinitis? *Annals of Allergy Asthma & Immunology* 90 (5): 466-468, May 2003.

Ratner PH., Howland WC., Arastu R., et al. Fluticasone Propionate Aqueous Nasal Spray Provided Significantly Greater Improvement in Daytime and Nighttime Nasal Symptoms of Seasonal Allergic Rhinitis Compared with Montelukast. *Annals of Allergy Asthma & Immunology* 90 (5): 536-542, May 2003.

Bukstein DA., Luskin AT., Bernstein A. "Real-World" Effectiveness of Daily Controller Medicine in Children with Mild Persistent Asthma. *Annals of Allergy Asthma & Immunology* 90 (5): 543-549, May 2003.

Higashi N., Taniguchi M., Mita H., et al. Nasal Blockage and Urinary Leukotriene E4 Concentration in Patients with Seasonal Allergic Rhinitis. *Allergy* 58 (6): 476-480, June 2003.

Ratner P., Hampel F., Gispert J. Efficacy of Ebastine in the Control of Nasal Congestion Associated with Allergic Rhinitis. *Methods and Findings in Experimental and Clinical Pharmacology* 25 (2): 111-115, March 2003.

Bousquet J., Van Cauwenberge P., Bachert C., et al. Requirements for Medications Commonly Used in the Treatment of Allergic Rhinitis – European Academy of Allergy and Clinical Immunology (EAACI) Allergic Rhinitis and its Impact on Asthma (ARIA). *ALLERGY* 58 (3): 192-197, March 2003.

Simons FER., Prenner BM., Finn A. Efficacy and Safety of Desloratadine in the Treatment of Perennial Allergic Rhinitis. *Journal of Allergy and Clinical Immunology* 111 (3): 617-622, March 2003.

Dubus JC., Anhoj I. A Review of Once-Daily Delivery of Anti-Asthmatic Drugs in Children. *Pediatric Allergy and Immunology* 14 (1): 4-9, Feb. 2003.

Miller FG., Wendler D., Wilfond B. When do the Federal Regulations Allow Placebo-Controlled Trials in Children? *Journal of Pediatrics* 142 (2): 102-107, Feb. 2003.

Nathan, RA. Pharmacotherapy for Allergic Rhinitis: A Critical Review of Leukotriene Receptor Antagonists Compared with Other Treatments. *Annals of Allergy Asthma & Immunology* 90 (2): 182-191, Feb. 2003.

van Adelsberg J., Philip G., LaForce CF., et al. Randomized Controlled Trial Evaluating the Clinical Benefit of Montelukast for Treating Spring Seasonal Allergic Rhinitis. *Annals of Allergy Asthma & Immunology* 90 (2): 214-222, Feb. 2003.

Buhl R. Omalizumab (Xolair®) Improves Quality of Life in Adult Patients with Allergic Asthma: A Review. *Respiratory Medicine* 97 (2): 123-129, Feb. 2003.

Limon L., Kockler DR. Desloratadine: A Nonsedating Antihistamine. *Annals of Pharmacotherapy* 37 (2): 237-246, Feb. 2003.

Skoner DP., Gentile D., Angelini B., et al. The Effects of Intranasal Triamcinolone Acetonide and Intranasal Fluticasone Propionate on Short-Term Bone Growth and HPA Axis in Children with Allergic Rhinitis. *Annals of Allergy Asthma & Immunology* 90 (1): 56-62, Jan. 2003.

Hogger P. Dose Response and Therapeutic Index of Inhaled Corticosteroids in Asthma. *Current Opinion in Pulmonary Medicine* 9 (1): 1-8, Jan. 2003.

Demoly P., Bousquet J. New H1-Antihistamines in Rhinitis. *Revue Francaise D Allergologie et D Immunologie Clinique* 43 (1): 64-68, Jan. 2003.

Borchard U. New H-1 Antihistamines in Comparison. *Allergologie* 26 (1): 24-32, Jan. 2003.

Bernardelli P., Gaudilliere B., Vergne F. To Market, to Market – 2001. *Annual Reports in Medicinal Chemistry* 37: 257-277, 2002.

Narayanan S., Edelman JM., Berger ML., et al. Asthma Control and Patient Satisfaction Among Early Pediatric Users of Montelukast. *J Asthma* 39 (8): 757-65, Dec. 2002.

Berger WE., Schenkel EJ., Mansfield LE. Safety and Efficacy of Desloratadine 5 mg in Asthma Patients with Seasonal Allergic Rhinitis and Nasal Congestion. *Annals of Allergy Asthma & Immunology* 89 (5): 485-491, Nov. 2002.

Wilson AM., Haggart K., Sims EJ., et al. Effects of Fexofenadine and Desloratadine on Subjective and Objective Measures of Nasal Congestion in Seasonal Allergic Rhinitis. *Clinical and Experimental Allergy* 32 (10): 1504-1509, Oct. 2002.

DuBuske LM. Pharmacology of Desloratadine – Special Characteristics. *Clinical Drug Investigation* 22 Suppl.2: 11, 2002.

Scadding GK. Desloratadine in the Treatment of Nasal Congestion in Seasonal Allergic Rhinitis – Preclinical Evidence. *Clinical Drug Investigation* 22 Suppl.2: 21-32, 2002.

Bachert C., Virchow CJ., Plenker A. Desloratadine in the Treatment of Seasonal Allergic Rhinitis – Results of a Large Observational Study. *Clinical Drug Investigation* 22 Suppl.2: 43-52, 2002.

Simons FER. Desloratadine: Clinical Pharmacokinetics of a Novel H-1 Receptor Antagonist – Foreword. *Clinical Pharmacokinetics* 41 Suppl.1: 4, 2002.

Schenkel E., Corren J., Murray JJ. Efficacy of Once-Daily Desloratadine/Pseudoephedrine for Relief of Nasal Congestion. *Allergy and Asthma Proceedings* 23 (5): 325-330, Sep.-Oct. 2002.

Hallstrand TS., Henderson WR. Leukotriene Modifiers. *Medical Clinics of North America* 86 (5): 1009-1035, Sep. 2002.

Riccioni G., Santilli F., D’Orazio N., et al. The Role of Antileukotrienes in the Treatment of Asthma. *International Journal of Immunopathology and Pharmacology* 15 (3): 171-182, Sep.-Dec. 2002.

Cabre F., Carabaza A., Garcia AM., et al. Pharmacological Profile of MEN91507, a New CysLT(1) Receptor Antagonist. *European Journal of Pharmacology* 451 (3): 317-326, Sep. 20, 2002.

Dupclay L., Doyle J. Assessment of Intranasal Corticosteroid Use in Allergic Rhinitis: Benefits, Cost, and Patient Preferences. *American Journal of Managed Care* 8 (13): S335-S340 Suppl. S, Sep. 2002.

Chervinsky P., Nelson HS., Bernstein DL., et al. Comparison of Mometasone Furoate Administered by Metered Dose Inhaler with Beclomethasone Dipropionate. *International Journal of Clinical Practice* 56 (6): 419-425, Jul.-Aug. 2002.

Stanley J. Szeffler, MD, John Warner, MD, Doris Staab, MD, et al. Switching from Conventional to Extrafine Aerosol Beclomethasone Dipropionate Therapy in Children: A 6-Month, Open-Label, Randomized Trial. *Journal of Allergy and Clinical Immunology*, Vol. 110 no. 1: p45-50 July 2002.

Ducharme FM. Anti-Leukotrienes as Add-On Therapy to Inhaled Glucocorticoids in Patients with Asthma: Systematic Review of Current Evidence. *BMJ* 324 (7353): 1545, June 29, 2002.

Pullerits T., Praks L., Ristioja V., et al. Comparison of a Nasal Glucocorticoid, Antileukotriene, and a Combination of Antileukotriene and Antihistamine in the Treatment of Seasonal Allergic Rhinitis. *J Allergy Clin Immunol* 109 (6): 949-55, June 2002.

Newman SP., Busse WW. Evolution of Dry Powder Inhaler Design, Formulation, and Performance. *Respiratory Medicine* 96 (5): 293-304, May 2002.

Yurdakul AS., Calisir HC., Tunctan B., et al. Comparison of Second Controller Medications in Addition to Inhaled Corticosteroid in Patients with moderate Asthma. *Respiratory Medicine* 96 (5): 322-329, May 2002.

Hochhaus G., Gonzalez MA., Dockhorn RJ., et al. A New Solution-Based Intranasal Triamcinolone Acetonide Formulation in Patients with Perennial Allergic Rhinitis: How Does the Pharmacokinetic/Pharmacodynamic Profile for Cortisol Suppression Compare with an Aqueous Suspension-Based Formulation? *Journal of Clinical Pharmacology* 42 (6): 662-669, June 2002.

Umland SP., Schleimer RP., Johnston SL. Review of the Molecular and Cellular Mechanisms of Action of Glucocorticoids for Use in Asthma. *Pulmonary Pharmacology & Therapeutics* 15 (1): 35-50, 2002.

Perkins HS. Balancing Self and Patient in the Physician-Patient Relationship. *CHEST* 121 (4): 1019-1021, April 2002.

Meltzer EO. Clinical Evidence for Antileukotriene Therapy in the Management of Allergic Rhinitis. *Ann Allergy Asthma Immunol* 88 (4 Suppl 1): 23-9, April 2002.

Miller FG., Shorr AF. Ethical Assessment of Industry-Sponsored Clinical Trials – A Case Analysis. *CHEST* 121 (4): 1337-1342, April 2002.

Dekhuijzen PNR., Koopmans PP. Pharmacokinetics Profile of Zafirlukast. *Clinical Pharmacokinetics* 41 (2): 105-114, 2002.

DeBoer DJ., Schafer JH., Salsbury CS., et al. Multiple-Center Study of Reduced-Concentrated Triamcinolone Topical Solution for the Treatment of Dogs with Known or Suspected Allergic Pruritus. *American Journal of Veterinary Research* 63 (3): 408-413, March 2002.

Bayes M., Rabasseda X., Prous JR. Gateways to Clinical Trials – March 2002. *Methods and Findings in Experimental and Clinical Pharmacology* 24 (2): 95-118, March 2002.

Hochhaus G., Sahasranaman S., Derendorf H., et al. Intranasal Glucocorticoid Delivery: Competition Between Local and Systemic Effects. *STP Pharma Sciences* 12 (1): 23-31, Jan.-Feb. 2002.

Weinstein SF. Combination Therapy in the Treatment of Allergic Rhinitis. *Allergy Asthma Proc.* 23 (1): 1-3, Jan.-Feb. 2002.

Croxtall JD., van Hal PTW., Choudhury Q., et al. Different Glucocorticoids Vary in Their Genomic and Non-Genomic Mechanism of Action in A549 Cells. *British Journal of Pharmacology* 135 (2): 511-519, Jan. 2002.

Bousquet J., Ben-Joseph R., Messonnier M., et al. A Meta-Analysis of the Dose-Response Relationship of Inhaled Corticosteroids in Adolescents and Adults with Mild to Moderate Persistent Asthma. *Clinical Therapeutics* 24 (1): 1-20, Jan. 2002.

Leff AR. Regulations of Leukotrienes in the Management of Asthma: Biology and Clinical Therapy. *Annual Review of Medicine* 52: 1-14, 2001.

Miller FG, Shorr AF. Salmeterol and inhaled corticosteroids in patients with persistent asthma. *JAMA* 286 (24):3075-3076 DEC 26, 2001.

Lipworth BJ. Emerging role of antileukotriene therapy in allergic rhinitis. *Clin. Exp. Allergy* 31(12): 1813-1821 Dec. 2001.

Nelson HS. Combination Therapy of Bronchial Asthma. *Allergy Asthma Proc.* 22 (4): 217-220, Jul.-Aug. 2001

Strek ME. Antileukotriene Working Group. Consensus Guidelines for Asthma Therapy. *Ann Allergy Asthma Immunol* 86 (6 Suppl 1): 40-44, June 2001.

Korenblat PE. Antileukotriene Working Group. The Role of Antileukotrienes in the Treatment of Asthma. *Ann Allergy Asthma Immunol* 86 (6 Suppl 1): 31-39, June 2001.

Flood-Page P., Barnes NC. What are the Alternatives to Increasing Inhaled Corticosteroids for the Long Term Control of Asthma. *Biodrugs* 15 (3): 185-198, 2001.

Sharpe M., Jarvis B. Inhaled mometasone furoate – A review of its use in adults and adolescents with persistent asthma. *Drugs* 61 (9): 1325-1350 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Mometasone Furoate Antagonizes AMP-Induced Bronchoconstriction in Patients with Mild Asthma. *Journal of Allergy and Clinical Immunology*, 105 (5) :906-11, May 2000. Authors: S.T. Holgate, H. Arshad, P. Stryszak, J.E. Harrison.

Affrime MB, Kosoglou T., Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. *Chest* 118 (6): 1538-1546 Dec. 2000. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. *Journal of Allergy and Clinical Immunology* 106 (3): 485-492 Sept. 2000. . Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Yang TT, Li S, Wyka B, et al. Drug delivery performance of the mometasone furoate dry powder inhaler. *Journal of Aerosol Medicine* 14 (4): 487-494 WIN 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Inman MD., Watson RM., Rerecich T., et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. *American Journal of Respiratory and Critical Care Medicine* 164 (4): 569-574 Aug. 15, 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Nelson H.S. Corticosteroid dosing and asthma control. *Annals of Allergy, Asthma, and Immunology* 86 (6): 599-602 June 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

O'Connor B., Bonnaud G., Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. *Annals of Allergy, Asthma, and Immunology* 86 (4): 397-404 April 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Fish J.E., Karpel J.P., Craig T.J., et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. *Journal of Allergy and Clinical Immunology* 106 (5): 852-860 Nov. 2000. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Nathan R.A., Nayak A.S., Graft D.F., et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. *Annals of Allergy, Asthma, and Immunology* 86 (2): 203-210 Feb. 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Noonan M., Karpel J.P., Bensch G.W., et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. *Annals of Allergy, Asthma, and Immunology* 86 (1): 36-46 Jan. 2001. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Pickering H., Pitcairn G.R., Hurst P.H., et al. Regional lung deposition of technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. *Clinical Therapy* (12): 1483-1493 December 2000. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

Bousquet J., D'Urzo A., Hebert J., et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler (R). *European Respiratory Journal* 16 (5): 808-816 November 2000. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. *Annals of Allergy, Asthma and Immunology*, 84(4):417-424, April 2000.

DuBuske LM. Mediator antagonists in the treatment of allergic disease. *Allergy Asthma Proc.*, 22(5):261-275, September–October 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Cazzola M., Centanni S., Boveri B., et al. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. *Respiration*, 68 (5):452-459 Sept-Oct 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Cates C. Extracts from "Clinical evidence"- Chronic asthma. *British Medical Journal*, 323 (7319):976-979, Oct. 27, 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Nathan RA, Kemp JP. Efficacy of antileukotrienes agents in asthma management. *Annals of Allergy, Asthma and Immunology*, 86 (6):9-17 Suppl. 1, June 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Korenblat PE. The role of antileukotrienes in the treatment of asthma. *Annals of Allergy, Asthma and Immunology*, 86 (6):31-39 Suppl. 1, June 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomized double-blind placebo-controlled trial. *Lancet*, 357 (9273):2007-2011, June 23, 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Dunn CJ, Goa KL. Zafirlukast – An update of its pharmacology and therapeutic efficacy in asthma. *Drugs*, 61 (2):285-315, 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Bisgaard H. Leukotriene modifiers in pediatric asthma management. *Pediatrics*, 107 (2):381-390, February 2001. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Dempsey OJ. Leukotriene receptor antagonist therapy. *Postgrad Medical Journal*, 76 (902):767-773, December 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Chung KF, Naya I. Compliance with an oral asthma medication: a pilot study using an electronic monitoring device. *Respiratory Medicine*, (9):852-858, Sept. 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Pearlman DS, Lampl KL, Dowling PJ, et al. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. *Clin. Ther.*, 22(6):732-747, June 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. *Journal of Allergy and Clinical Immunology*, 105 (6): 1123-1129 Part 1, June 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. *Thorax*, 55 (6): 478-483, June 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Kemp JP, Korenblat PE, Scherger JE, et al. Zafirlukast in clinical practice – Results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. *Journal of Family Practice*, 48 (6): 425-432, June 1999. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Jarvis B, Markham A. Montelukast – A review of its therapeutic potential in persistent asthma. *Drugs*, 59 (4): 891-928, April 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Weinberg EG, Naya I. Treatment preferences of adolescent patients with asthma. *Pediatric Allergy and Immunology*, 11 (1): 49-55, February 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Virchow JC. Asthma therapy with mediator-antagonists. *Allergologie*, 23 (2): 81-91, February 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Korenblat PE, Kemp JP, Scherger JE, et al. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoeconomics Trial (ACCEPT). *Annals of Allergy, Asthma and Immunology*, 84 (2): 217-225, February 2000. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Magnan A, Vervloet D. Antileukotrienes (3): their place in the treatment of asthma. *Rev. Fr. Allergol*, 39 (7): 546-550, 1999. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Price J, Kemp J. The problems of treating adolescent asthma: what are the alternatives to inhaled therapy? *Respiratory Medicine*, 93 (10): 677-684, October 1999. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Sanico AM, Kita H, Leiferman KM, et al. Eosinophilia in 23-year-old woman with asthma. *Annals of Allergy, Asthma and Immunology*, 83 (3): 193-199, September 1999. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Grossman J, Smith LJ, Wilson AM, et al. Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. *Annals of Allergy, Asthma and Immunology*, 82 (4): 361-369, April 1999. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

Tashkin DP, Natan RA, Howland WC, et al. An evaluation of Zafirlukast in the treatment of asthma with exploratory subset analyses. *Journal of Allergy and Clinical Immunology*, 103 (2): 246-254 Part 1, February 1999. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. *Journal of Allergy and Clinical Immunology*, 102(6):935, Part 1, December 1998.

(Anon.). Desloratadine – Sch-34117 – Aerius (R)-Neoclarity (R) – Clairinex (R) – Treatment of allergic rhinitis – Treatment of Urticaria. *Drug Future*, 26 (4): 404-407, April 2001. Efficacy and tolerability of once-daily 5mg desloratadine, an H-1-receptor antagonist, in patients with seasonal allergic rhinitis – Assessment during the spring and fall allergy seasons. *Clinical Drug Investigation*, 21 (1): 25-32, 2001.

McClellan K, Jarvis B. Desloratadine. *Drugs*, 61 (6): 789-796, 2001. Efficacy and tolerability of once-daily 5mg desloratadine, an H-1-receptor antagonist, in patients with seasonal allergic rhinitis – Assessment during the spring and fall allergy seasons. *Clinical Drug Investigation*, 21 (1): 25-32, 2001.

Geha RS, Meltzer EO. Desloratadine: A new, nonsedating oral antihistamine. *Journal of Allergy and Clinical Immunology*, 107 (4): 752-762, April 2001. Efficacy and tolerability of once-daily 5mg desloratadine, an H-1-receptor antagonist, in patients with seasonal allergic rhinitis – Assessment during the spring and fall allergy seasons. *Clinical Drug Investigation*, 21 (1): 25-32, 2001.

Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebo-controlled, parallel-group study. *Clinical Therapy*, 23 (3): 451-466, March 2001. Efficacy and tolerability of once-daily 5mg desloratadine, an H-1-receptor antagonist, in patients with seasonal allergic rhinitis – Assessment during the spring and fall allergy seasons. *Clinical Drug Investigation*, 21 (1): 25-32, 2001.

Watelet JB, Vermeiren J, Van Cauwenberge P. Efficacy of intranasal treatment in children with rhinitis allergy. *Rev. Fr. Allergol.*, 41 (7): 628-633, November 2001. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Bousquet J., van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. *Journal of Allergy, Asthma and Immunology*, 108 (5): S147-S334 Suppl. S, Nov. 2001. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Szeffler SJ. Pharmacokinetics of intranasal corticosteroids. *Journal of Allergy and Clinical Immunology*, 108 (1): S26-S31 Suppl. S, July 2001. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Boner AL. Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. *Journal of Allergy and Clinical Immunology*, 108 (1): S32-S39 Suppl. S, July 2001. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 108 (1): S59-S64 Suppl. S, July 2001. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Klossek JM, Laliberte F, Laliberte MF, et al. Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosal in the long term treatment of perennial allergic rhinitis. *Rhinology*, 39 (1): 17-22, March 2001. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Allen DB. Systemic effects of intranasal steroids: An endocrinologist's perspective. *Journal of Allergy and Clinical Immunology*, 106 (4): S179-S4190 Suppl. S, October 2000. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Gawchik SM, Saccar CL. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. *Drug Safety*, 23 (4): 309-322, October 2000. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Virant FS. Allergic rhinitis. *Immunol. Allergy Clin.*, 20 (2): 265-+, May 2000. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Williams PV. Treatment of rhinitis – Corticosteroids and cromolyn sodium. *Immunol. Allergy Clin.*, 20 (2): 369-+, May 2000. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Durham SR. The inflammatory nature of allergic disease. *Clin. Exp. Allergy*, 28: 20-24 Suppl. 6, December 1998. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare? *Journal of Allergy and Clinical Immunology*, 104 (4): S144-S149 Part 1, Oct. 1999. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. *Journal of Allergy and Clinical Immunology*, 101 (2): 157-162, Part 1, February 1998.

Meltzer EO. Role for Cysteinyl Leukotriene Receptor Antagonist Therapy in Asthma and Their Potential Role in Allergic Rhinitis Based on the Concept of "One Linked Airway Disease". *Annals of Allergy and Asthma Feb 2000:84(2):176-85;quiz185-7*. Addition of Zafirlukast Compared with a Doubled-Dosage of Inhaled Corticosteroids in Asthmatic Patients with Symptoms on Inhaled Corticosteroids. *European Respiratory Journal 12(Suppl 28):P2388*, 1998. Authors: Nayak AS, Anderson, PJ, Carous KL.

Barnes NC. Effects of Antileukotrienes in the Treatment of Asthma. *American Journal of Respiratory and Critical Care Medicine Feb 2000:161(2 Pt 2):S73-6*. The Effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *The Journal of Allergy and Clinical Immunology 101(2) (Part1): 157-162*, 1998.

Lipworth BJ, Jackson CM. Safety of Inhaled and Intranasal Corticosteroids: Lessons for the New Millennium. *Drug Safety July 2000:23(1):11-33*. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, Simpson B, Mullin ME, Smith JA. The effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *Journal of Allergy and Clinical Immunology Feb 1998:102(2 Pt 1):157-62*.

Lang DM. Antileukotriene Agents and Aspirin-Sensitive Asthma: Are We Removing the Second Bassoonist or Skating to Where the Puck is Gonna Be? *Annals of Allergy and Asthma July 2000;85(1):5-8*. The Effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *The Journal of Allergy and Clinical Immunology 101(2) (Part1): 157-162, 1998*.

Laliberte F, Laliberte MF, Lecart S, Bousquet J, Klossec JM, Mounedji N. Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids. *Allergy August 2000;55(8):718-22*. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, Simpson B, Mullin ME, Smith JA. The Effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *Journal of Allergy and Clinical Immunology Feb 1998;102(2 Pt 1):157-62*.

Holgate St, Arshad H, Stryszak P, Harrison Je. Mometasone Furoate Antagonizes AMP-Induced Bronchoconstriction in Patients with Mild Asthma. *Journal of Allergy and Clinical Immunology May 2000;105(5):906-11*. A Six-Month, Placebo-Controlled Comparison of the Safety and Efficacy of Salmeterol or Beclomethasone for Persistent Asthma. *Annals of Allergy, June 1999*.

Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Druham Sr, Fokkens WJ, Howarth PH, Lund V, Malling HJ, Mygind N, Passali D, Scadding GK, Wang DY. Consensus Statement on the Treatment of Allergic Rhinitis. *Allergy Feb 2000;55(2):116-34*. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, Simpson B, Mullin ME, Smith JA. The effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *Journal of Allergy and Clinical Immunology Feb 1998;102(2 Pt 1):157-62*.

Jarvis B, Markham A. Montelukast: A Review of its Therapeutic Potential in Persistent Asthma. *Drugs April 2000;59(4):891-928*. The Effects of Triamcinolone Acetonide Aqueous Nasal Spray on Adrenocortical Function in Children with Allergic Rhinitis. *The Journal of Allergy and Clinical Immunology 101(2) (Part1): 157-162, 1998*.

A Comparison of the Efficacy of Fluticasone Propionate Aqueous Nasal Spray and Loratadine, Alone and in Combination, for the Treatment of Seasonal Allergic Rhinitis. *Journal of Family Practice 47(2):118-125, August 1998*. Authors: P.H. Ratner, J.H. van Bavel, B.G. Martin, F.C. Hampel Jr., W.C. Howland III, P.R. Rogenes, R.E. Westlund, B.W. Bowers, C.K. Cook.

Inhaled Fluticasone Propionate Delivered by Means of Two Different Multidose Powder Inhalers is Effective and Safe in a Large Pediatric Population with Persistent Asthma. *Journal of Allergy and Clinical Immunology 102(1) 32-38, July 1998*. Authors: D.B. Peden, W.E. Berger, M.J. Noonan, M.R. Thomas, V.L. Hendricks, A.G. Hamedani, P. Mahajan, K.W. House.

Montelukast a Once Daily CysLT<sub>1</sub> Receptor Antagonist in the Treatment of Chronic Asthma, A Multicenter, Randomized, Double-Blind Trial. *The Archives of Internal Medicine Volume 158 (11):1213-20, June 8, 1998*. (contributor) Authors: T.F. Reiss, P. Chervinsky, R.J. Dockhorn, S. Shingo, B. Seidenberg, T.B. Edwards.

Intranasal Fluticasone Propionate. A Reappraisal of its Pharmacology and Clinical Efficacy in the Treatment of Rhinitis. *Drugs 53(5):885-907, May 1997*. Authors: L.R. Wiseman, P. Benfield.

Clinical Uses of Intravenous Immunoglobulin in Pregnancy. *American Journal of Obstetrics and Gynecology*, 176 (1 PT 1):241-253, January 1997. Authors: A.L. Clark, S.A. Gall.  
Switching from Conventional to Extrafine Aerosol Beclomethasone Dipropionate Therapy in Children: